Inhaled AER101 before lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This early-stage trial tests a new inhaled medication (AER101) given before surgery for newly diagnosed lung cancer. The goal is to see if it helps shrink tumors or make surgery safer and more effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been recently diagnosed with lung adenocarcinoma or squamous cell carcinoma (two common types of lung cancer)
- Your cancer is in your lungs only—not spread to lymph nodes or other parts of your body (though multiple tumors in the lungs are okay)
- You are a good candidate for surgery and willing to have it
- You had a PET/CT scan (a type of imaging test) at Stephenson Cancer Center within the last 30 days
- You are able to understand and agree to follow the study plan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether giving different cancer medicines before (and sometimes after) surgery improves outcomes for people with early-stage, operable lung cancer that has certain tumor markers. It may help by trying to shrink or control the cancer early and lower the chance it comes back.
This trial looks at giving immunotherapy before surgery for certain early-stage lung cancers to help shrink the tumor and improve outcomes. It is mainly for people whose lung cancer can be removed by surgery and who don’t have specific gene changes like EGFR or ALK.
This trial tests whether taking lazertinib before surgery can shrink or control EGFR-mutant lung adenocarcinoma that can be fully removed by an operation. It uses a special liquid biopsy from fluid in the lungs to confirm the EGFR mutation and guide treatment.
This trial tests a combination of radiation therapy, an immunotherapy drug called toripalimab, and chemotherapy given before surgery for stage II-III non-small cell lung cancer. The goal is to shrink the tumor before removal and improve survival outcomes.
This trial tests a combination of two drugs (SHR-A1811 and Adebelimumab) given before surgery for people with a specific type of lung cancer that has changes in the HER2 gene. The goal is to see if this treatment can shrink the tumor and make surgery more effective.
This trial studies a comprehensive treatment approach for lung cancer that combines immunotherapy given before surgery with standard surgery. It aims to understand how well this approach works by analyzing your medical data and samples.
Hear when a new Non-small Cell Lung Cancer Stage I trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.